Last reviewed · How we verify

Levocetirizine (drug) — Competitive Intelligence Brief

Levocetirizine (drug) (Levocetirizine (drug)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist (second-generation antihistamine). Area: Allergy/Immunology.

marketed H1-receptor antagonist (second-generation antihistamine) H1-receptor Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Levocetirizine (drug) (Levocetirizine (drug)) — UCB Pharma. Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Levocetirizine (drug) TARGET Levocetirizine (drug) UCB Pharma marketed H1-receptor antagonist (second-generation antihistamine) H1-receptor
Bepreve BEPOTASTINE Bausch Health marketed Histamine-1 Receptor Antagonist H1-receptor, mast cells 2009-01-01
bepotastine besilate ophthalmic solution bepotastine besilate ophthalmic solution Bausch & Lomb Incorporated marketed H1-receptor, mast cells
olopatadine 0.2% ophthalmic solution olopatadine 0.2% ophthalmic solution Allergan marketed H1-receptor antagonist H1-receptor
Cetirizine Dry Syrup Cetirizine Dry Syrup GlaxoSmithKline phase 3 H1-receptor antagonist (second-generation antihistamine) H1-receptor
Antihistamine Cetirizine Hydrochloride Antihistamine Cetirizine Hydrochloride Goldman, Butterwick, Fitzpatrick and Groff marketed H1-receptor antagonist (second-generation antihistamine) H1 histamine receptor
Cetirizine (Zyrtec) Cetirizine (Zyrtec) Organon and Co marketed H1-receptor antagonist (second-generation antihistamine) H1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist (second-generation antihistamine) class)

  1. UCB Pharma · 5 drugs in this class
  2. Organon and Co · 3 drugs in this class
  3. Brian J Lipworth · 1 drug in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Goldman, Butterwick, Fitzpatrick and Groff · 1 drug in this class
  6. HK inno.N Corporation · 1 drug in this class
  7. AAADRS Clinical Research Center · 1 drug in this class
  8. University Hospital, Grenoble · 1 drug in this class
  9. Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levocetirizine (drug) — Competitive Intelligence Brief. https://druglandscape.com/ci/levocetirizine-drug. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: